Inhibitors of HSP90 Block P95-Her2 Signaling in Trastuzumab-Resistant Tumors and Suppress Their Growth

Oncogene - United Kingdom
doi 10.1038/onc.2009.337
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cytokeratin 5/6 Fingerprinting in HER2-positive Tumors Identifies a Poor Prognosis and Trastuzumab-Resistant Basal-Her2 Subtype of Breast Cancer

Oncotarget
Oncology
2015English

Circumventing Hsp90 Inhibitors via Apoptosis Block

Oncoscience
Cancer ResearchOncology
2015English

Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib

AboutOpen
2018English

A Novel Toll-Like Receptor 9 Agonist Cooperates With Trastuzumab in Trastuzumab-Resistant Breast Tumors Through Multiple Mechanisms of Action

Clinical Cancer Research
Cancer ResearchOncology
2009English

HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2 + Tumors

Cancer Research
Cancer ResearchOncology
2017English

Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer

Journal of Cancer Research and Clinical Oncology
MedicineCancer ResearchOncology
2013English

HER2/ErbB2 Activates HSF1 and Thereby Controls HSP90 Clients Including MIF in HER2-overexpressing Breast Cancer

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2014English

Development of HER2-specific Humanized Antibody Herceptin (Trastuzumab).

Folia Pharmacologica Japonica
Pharmacology
2003English

Effects of a Second-Generation Human Anti-ErbB2 ImmunoRNase on Trastuzumab-Resistant Tumors and Cardiac Cells

Protein Engineering, Design and Selection
BiochemistryBioengineeringMolecular BiologyBiotechnology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy